1,920 Intuitive Surgical, Inc. $ISRG Shares Bought by First Citizens Bank & Trust Co.

First Citizens Bank & Trust Co. grew its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 9.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 22,884 shares of the medical equipment provider’s stock after acquiring an additional 1,920 shares during the quarter. First Citizens Bank & Trust Co.’s holdings in Intuitive Surgical were worth $9,305,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Invesco Ltd. increased its position in Intuitive Surgical by 17.4% during the 4th quarter. Invesco Ltd. now owns 4,128,735 shares of the medical equipment provider’s stock worth $2,338,350,000 after purchasing an additional 611,268 shares in the last quarter. Bank of America Corp DE raised its holdings in Intuitive Surgical by 3.3% in the first quarter. Bank of America Corp DE now owns 3,616,973 shares of the medical equipment provider’s stock valued at $1,667,388,000 after buying an additional 116,292 shares during the period. Bank of New York Mellon Corp purchased a new stake in Intuitive Surgical during the second quarter worth approximately $1,335,753,000. Amundi increased its position in shares of Intuitive Surgical by 8.6% in the first quarter. Amundi now owns 2,428,356 shares of the medical equipment provider’s stock worth $1,119,448,000 after acquiring an additional 193,096 shares in the last quarter. Finally, J. Stern & Co. LLP increased its position in shares of Intuitive Surgical by 18,504.6% in the fourth quarter. J. Stern & Co. LLP now owns 2,127,248 shares of the medical equipment provider’s stock worth $1,204,788,000 after acquiring an additional 2,115,814 shares in the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Oppenheimer upgraded Intuitive Surgical from a “market perform” rating to an “outperform” rating and set a $500.00 price target for the company in a report on Wednesday, August 12th. Wall Street Zen lowered Intuitive Surgical from a “buy” rating to a “hold” rating in a research note on Sunday, September 20th. Royal Bank Of Canada reduced their price target on Intuitive Surgical from $650.00 to $600.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. Piper Sandler reaffirmed an “overweight” rating on shares of Intuitive Surgical in a report on Friday, August 21st. Finally, UBS Group reaffirmed a “buy” rating on shares of Intuitive Surgical in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $498.83.

Intuitive Surgical News Roundup

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Erste Group Bank raised its FY2026 EPS forecast for Intuitive Surgical to $8.94 from $8.93, above the consensus estimate of $8.87. The firm also increased its FY2027 forecast to $10.09 from $10.06, indicating modestly improving expectations for long-term profitability. MarketBeat Intuitive Surgical analyst estimates
• Positive Sentiment: Zacks upgraded ISRG to a Rank #2, or “Buy,” citing improving earnings prospects. UBS also reiterated its Buy rating and maintained a $500 price target, pointing to the company’s long-term robotic-surgery growth runway. Zacks upgrade article UBS Buy rating article
• Positive Sentiment: Intuitive Surgical’s submission of a next-generation robotic endoscope to the FDA could expand the company beyond surgical procedures into gastrointestinal care. Approval would create an additional growth opportunity, although the timing and outcome remain uncertain. ISRG GI opportunity article
• Neutral Sentiment: Investor attention remains elevated ahead of the company’s expected quarterly earnings release. Recent coverage highlights ISRG’s strong sales growth, cash generation and debt-free balance sheet, but also notes that the shares trade at a substantially higher valuation than some healthcare peers.
• Negative Sentiment: BTIG lowered its price target to $454 from $469 while retaining a Buy rating. The reduction suggests more limited near-term upside despite continued confidence in the business. BTIG price target article
• Negative Sentiment: One valuation analysis argues that ISRG could be about 31% overvalued following its earnings-outlook upgrade. With a price-to-earnings ratio near 48 based on the supplied market data, strong execution may already be reflected in the stock price.

Insiders Place Their Bets

In related news, EVP Gary Loeb sold 400 shares of Intuitive Surgical stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $379.00, for a total value of $151,600.00. Following the completion of the transaction, the executive vice president directly owned 5,320 shares in the company, valued at approximately $2,016,280. This trade represents a 6.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gary Guthart sold 10,000 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $400.00, for a total value of $4,000,000.00. Following the completion of the sale, the director directly owned 1,245,679 shares of the company’s stock, valued at approximately $498,271,600. This represents a 0.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 12,370 shares of company stock valued at $4,891,989. 0.60% of the stock is owned by company insiders.

Intuitive Surgical Price Performance

NASDAQ ISRG opened at $422.06 on Wednesday. Intuitive Surgical, Inc. has a 12 month low of $328.57 and a 12 month high of $603.88. The company has a market capitalization of $149.11 billion, a price-to-earnings ratio of 48.35, a price-to-earnings-growth ratio of 3.23 and a beta of 1.46. The company’s fifty day moving average price is $388.49 and its two-hundred day moving average price is $410.14.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.48 by $0.32. The company had revenue of $2.89 billion during the quarter, compared to the consensus estimate of $2.83 billion. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. The company’s revenue was up 18.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.81 EPS. As a group, analysts anticipate that Intuitive Surgical, Inc. will post 8.87 EPS for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops and commercializes robotic-assisted systems and related technologies designed to support minimally invasive medical procedures. The company’s products are intended to help surgeons perform operations through small incisions while providing enhanced visualization, precision, and control.

Its principal product is the da Vinci Surgical System, a platform used across a range of specialties, including general surgery, urology, gynecology, thoracic surgery, and cardiac procedures.